Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Extended-spectrum beta-lactamases.

J M Blondeau1

  • 1Department of Clinical Microbiology, Royal University and Saskatoon City Hospitals, Saskatchewan, Canada. blondeauj@sdh.sk.ca

Seminars in Respiratory Infections
|September 20, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Urinary tract infection in a human male patient with <i>Staphylococcus pseudintermedius</i> transmission from the family dog.

Journal of chemotherapy (Florence, Italy)·2021
Same author

Persistent infection with <i>Staphylococcus pseudintermedius</i> in an adult oncology patient with transmission from a family dog.

Journal of chemotherapy (Florence, Italy)·2020
Same author

A pilot study investigating the in vitro efficacy of sucralfate against common veterinary cutaneous pathogens.

The Journal of small animal practice·2018
Same author

Killing of Streptococcus pneumoniae by azithromycin, clarithromycin, erythromycin, telithromycin and gemifloxacin using drug minimum inhibitory concentrations and mutant prevention concentrations.

International journal of antimicrobial agents·2015
Same author

Mutant prevention concentration of tigecycline for clinical isolates of Streptococcus pneumoniae and Staphylococcus aureus.

The Journal of antimicrobial chemotherapy·2014
Same author

Comparative minimum inhibitory and mutant prevention drug concentrations of enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin against bovine clinical isolates of Mannheimia haemolytica.

Veterinary microbiology·2012

Extended-spectrum beta-lactamase (ESBL) producing bacteria are a growing concern due to increasing resistance to cephalosporins. This resistance leads to higher patient morbidity and mortality, posing significant clinical challenges.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Antimicrobial Resistance

Background:

  • Extended-spectrum beta-lactamase (ESBL) producing gram-negative bacilli represent a significant and increasing global health threat.
  • These bacteria exhibit resistance to crucial third-generation cephalosporin antibiotics, limiting treatment options for serious infections.
  • The rise in ESBL-producing organisms contributes to increased patient morbidity and mortality.

Purpose of the Study:

  • To discuss the growing concern of ESBL-producing gram-negative bacilli.
  • To highlight the resistance patterns of these organisms against third-generation cephalosporins.
  • To address the clinical implications and diagnostic challenges associated with ESBL producers.

Main Methods:

  • Literature review and synthesis of current research on ESBL-producing organisms.

Related Experiment Videos

  • Analysis of antimicrobial resistance mechanisms and trends.
  • Discussion of clinical case studies and laboratory detection methods.

    • Main Results:

    • ESBL-producing organisms are increasingly prevalent across various gram-negative species.
    • Resistance to third-generation cephalosporins is a defining characteristic, complicating inpatient management.
    • Detection of ESBL production can be challenging in clinical laboratories, potentially leading to delayed or inappropriate treatment.

    Conclusions:

    • The increasing prevalence and resistance of ESBL-producing bacteria necessitate urgent attention in clinical practice and research.
    • Effective detection and management strategies are crucial to mitigate the rising morbidity and mortality associated with these infections.
    • Further research into novel antimicrobial agents and diagnostic tools is warranted to combat the ESBL threat.